Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis.

Lastres-Becker I, Innamorato NG, Jaworski T, Rábano A, Kügler S, Van Leuven F, Cuadrado A.

Brain. 2014 Jan;137(Pt 1):78-91. doi: 10.1093/brain/awt323. Epub 2013 Nov 25.

PMID:
24277722
2.

Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/β-TrCP axis.

Rada P, Rojo AI, Evrard-Todeschi N, Innamorato NG, Cotte A, Jaworski T, Tobón-Velasco JC, Devijver H, García-Mayoral MF, Van Leuven F, Hayes JD, Bertho G, Cuadrado A.

Mol Cell Biol. 2012 Sep;32(17):3486-99. doi: 10.1128/MCB.00180-12. Epub 2012 Jul 2.

3.

α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease.

Lastres-Becker I, Ulusoy A, Innamorato NG, Sahin G, Rábano A, Kirik D, Cuadrado A.

Hum Mol Genet. 2012 Jul 15;21(14):3173-92. doi: 10.1093/hmg/dds143. Epub 2012 Apr 18.

PMID:
22513881
4.

Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice.

Martín-Moreno AM, Brera B, Spuch C, Carro E, García-García L, Delgado M, Pozo MA, Innamorato NG, Cuadrado A, de Ceballos ML.

J Neuroinflammation. 2012 Jan 16;9:8. doi: 10.1186/1742-2094-9-8.

5.

Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease.

Martín-Moreno AM, Reigada D, Ramírez BG, Mechoulam R, Innamorato N, Cuadrado A, de Ceballos ML.

Mol Pharmacol. 2011 Jun;79(6):964-73. doi: 10.1124/mol.111.071290. Epub 2011 Feb 24.

6.

Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism.

Jazwa A, Rojo AI, Innamorato NG, Hesse M, Fernández-Ruiz J, Cuadrado A.

Antioxid Redox Signal. 2011 Jun 15;14(12):2347-60. doi: 10.1089/ars.2010.3731. Epub 2011 Mar 28.

7.

Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1.

Innamorato NG, Jazwa A, Rojo AI, García C, Fernández-Ruiz J, Grochot-Przeczek A, Stachurska A, Jozkowicz A, Dulak J, Cuadrado A.

PLoS One. 2010 Jul 28;5(7):e11838. doi: 10.1371/journal.pone.0011838.

8.

Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease.

Rojo AI, Innamorato NG, Martín-Moreno AM, De Ceballos ML, Yamamoto M, Cuadrado A.

Glia. 2010 Apr;58(5):588-98. doi: 10.1002/glia.20947.

PMID:
19908287
9.

Role of microglial redox balance in modulation of neuroinflammation.

Innamorato NG, Lastres-Becker I, Cuadrado A.

Curr Opin Neurol. 2009 Jun;22(3):308-14. doi: 10.1097/WCO.0b013e32832a3225. Review.

PMID:
19359988
10.

The transcription factor Nrf2 is a therapeutic target against brain inflammation.

Innamorato NG, Rojo AI, García-Yagüe AJ, Yamamoto M, de Ceballos ML, Cuadrado A.

J Immunol. 2008 Jul 1;181(1):680-9.

Supplemental Content

Loading ...
Support Center